Holen Sie sich die Stockscreener-App
6.82
1.04%
0.07
Schlusskurs vom Vortag:
$6.75
Offen:
$6.74
24-Stunden-Volumen:
1.29M
Relative Volume:
0.46
Marktkapitalisierung:
$739.25M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-6.0893
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+0.74%
1M Leistung:
+37.22%
6M Leistung:
+124.34%
1J Leistung:
-30.76%
1-Tages-Spanne:
$6.68
$7.105
1-Wochen-Bereich:
$6.36
$7.105
52-Wochen-Spanne:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.82 | 731.66M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
What are analysts’ price targets for Tango Therapeutics Inc. in the next 12 monthsNavigate market shifts with confidence - jammulinksnews.com
Should I hold or sell Tango Therapeutics Inc. stock in 2025Capitalize on high-yield stocks early - jammulinksnews.com
Will Tango Therapeutics Inc. stock benefit from interest rate changesFree Best Performing Stock Suggestions - Newser
Tango Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveFree Stock Trading Signals - Newser
Can Tango Therapeutics Inc. stock recover from recent declineSolid Return Trade Selections - Newser
What drives Tango Therapeutics Inc. stock priceMassive portfolio appreciation - Autocar Professional
Will Tango Therapeutics Inc. stock benefit from AI tech trendsSuperior capital gains - jammulinksnews.com
Is Tango Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
What analysts say about Tango Therapeutics Inc. stockExplosive portfolio gains - Autocar Professional
Tango Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Optimistic Investors Push Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Up 31% But Growth Is Lacking - 富途牛牛
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
Tango Therapeutics Earnings Alert: Q2 2025 Results Coming August 5 Without Investor Call - Stock Titan
How Tango Therapeutics Inc. stock performs during market volatilityFree Consultation - Newser
How high can Tango Therapeutics Inc. stock price go in 2025Daily Volume Leaders - Newser
Can Tango Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
What makes Tango Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
Tango Therapeutics (TNGX) Soars 5.96% on Strong Q2 Earnings - AInvest
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 06 '24 |
Sale |
3.28 |
1,494,558 |
4,896,023 |
11,836,178 |
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):